We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Integra (IART) to Report Q1 Earnings: What's in the Offing?
Read MoreHide Full Article
Integra LifeSciences Holding Corporation (IART - Free Report) is scheduled to report first-quarter 2021 results on Apr 28, before the opening bell.
In the last reported quarter, the company’s earnings of $2.45 surpassed the Zacks Consensus Estimate by 3.8%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and missed on one, with the average surprise being 86.6%.
Let’s see how things have shaped up prior to this announcement.
Factors to Note
Just like the last reported quarter, operations in both the business segments might have remained challenging for Integra through the first quarter.
CSS
Integra’s Codman Specialty Surgical (CSS) segment’s results are expected to reflect potential growth in first-quarter 2021 on continued robust demand for market-leading products including DuraGen, antimicrobial catheters and service programmable valves. In the fourth quarter, robust sales of these products compensated the company’s pandemic-induced operating loss. With the health situation remaining more-or-less unchanged, this trend is expected to have been repeated in the to-be-reported quarter.
Furthermore, Integra registered revenue growth in Japan banking on strong customer adoption of the neurosurgery portfolio. This is expected to have once again contributed to the company’s top line. In China too, the distribution deal with local Chinese partner has been gaining larger market access. This is expected to have contributed to the CSS growth rate.
Integra LifeSciences Holdings Corporation Price and EPS Surprise
We expect the addition of ACell and expansion of the tissue technology platform to have driven first-quarter 2021 growth.
OTT
In January 2021, the company divested the non-core extremity orthopedic business within the Orthopedics and Tissue Technologies arm to focus more on the profitable part of the arm. During fourth-quarter earnings call, it noted that this discontinued business will have a negative impact on 2021 growth. We believe, this should reflect on first-quarter 2021 results as well.
However, as the pandemic took a graver form, demand for the Integra’s surgical procedures declined significantly, resulting in dramatic sales decline. During the company’s February update, the company noted that the recovery rate of surgical procedures and capital equipment sales should remain variable as the course of the pandemic remains uncertain. The slower recovery rate is likely to have impeded Integra’s first-quarter growth.
Estimate Picture
For first-quarter 2021, the Zacks Consensus Estimate for total revenues of $349.9 million implies a decline of 1.3% from the prior-year reported figure.
The consensus estimate for earnings per share is pegged at 56 cents, implying an improvement of 16.7% from the prior-year reported figure.
What Our Model Suggests
Our proven model does not conclusively predict an earnings beat for Integra this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Integra has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
HCA Healthcare, Inc. (HCA - Free Report) has an Earnings ESP of +8.91% and a Zacks Rank of 2, at present.
Avenue Therapeutics, Inc. (ATXI - Free Report) has an Earnings ESP of +16.67% and a Zacks Rank of 2, at present.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
Integra (IART) to Report Q1 Earnings: What's in the Offing?
Integra LifeSciences Holding Corporation (IART - Free Report) is scheduled to report first-quarter 2021 results on Apr 28, before the opening bell.
In the last reported quarter, the company’s earnings of $2.45 surpassed the Zacks Consensus Estimate by 3.8%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on three occasions and missed on one, with the average surprise being 86.6%.
Let’s see how things have shaped up prior to this announcement.
Factors to Note
Just like the last reported quarter, operations in both the business segments might have remained challenging for Integra through the first quarter.
CSS
Integra’s Codman Specialty Surgical (CSS) segment’s results are expected to reflect potential growth in first-quarter 2021 on continued robust demand for market-leading products including DuraGen, antimicrobial catheters and service programmable valves. In the fourth quarter, robust sales of these products compensated the company’s pandemic-induced operating loss. With the health situation remaining more-or-less unchanged, this trend is expected to have been repeated in the to-be-reported quarter.
Furthermore, Integra registered revenue growth in Japan banking on strong customer adoption of the neurosurgery portfolio. This is expected to have once again contributed to the company’s top line. In China too, the distribution deal with local Chinese partner has been gaining larger market access. This is expected to have contributed to the CSS growth rate.
Integra LifeSciences Holdings Corporation Price and EPS Surprise
Integra LifeSciences Holdings Corporation price-eps-surprise | Integra LifeSciences Holdings Corporation Quote
We expect the addition of ACell and expansion of the tissue technology platform to have driven first-quarter 2021 growth.
OTT
In January 2021, the company divested the non-core extremity orthopedic business within the Orthopedics and Tissue Technologies arm to focus more on the profitable part of the arm. During fourth-quarter earnings call, it noted that this discontinued business will have a negative impact on 2021 growth. We believe, this should reflect on first-quarter 2021 results as well.
However, as the pandemic took a graver form, demand for the Integra’s surgical procedures declined significantly, resulting in dramatic sales decline. During the company’s February update, the company noted that the recovery rate of surgical procedures and capital equipment sales should remain variable as the course of the pandemic remains uncertain. The slower recovery rate is likely to have impeded Integra’s first-quarter growth.
Estimate Picture
For first-quarter 2021, the Zacks Consensus Estimate for total revenues of $349.9 million implies a decline of 1.3% from the prior-year reported figure.
The consensus estimate for earnings per share is pegged at 56 cents, implying an improvement of 16.7% from the prior-year reported figure.
What Our Model Suggests
Our proven model does not conclusively predict an earnings beat for Integra this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) increases the chances of an earnings beat.
Earnings ESP: Integra has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering as these have the right combination of elements to beat on earnings this reporting cycle.
Elanco Animal Health Incorporated (ELAN - Free Report) currently has a Zacks Rank #1 and an Earnings ESP of +1.90%. You can see the complete list of today’s Zacks #1 Rank stocks here.
HCA Healthcare, Inc. (HCA - Free Report) has an Earnings ESP of +8.91% and a Zacks Rank of 2, at present.
Avenue Therapeutics, Inc. (ATXI - Free Report) has an Earnings ESP of +16.67% and a Zacks Rank of 2, at present.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>